Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-52. (Cancelled)

53. (Previously presented) A method for inducing a cellular immune response in a human subject directed to a PSCA protein of Fig. 1B SEQ ID NO:2, the subject having a cancer overexpressing a Prostate Stem Cell Antigen (PSCA) protein, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject a PSCA protein of Fig. 1B (SEQ ID NO:2) or an immunogenic fragment thereof.

54.-57. (Cancelled)

58. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

59. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

60. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.

61. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.

62. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.

63. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.

64. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.

65. (Canceled)

66. (Canceled)

67. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 99 as described in SEQ ID NO:2.

68. (Canceled)

69. (Canceled)

70. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.

71. (Previously presented) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.

72. (Canceled)

73. (Cancelled)

74. (Previously presented) The method of claim 53, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.

75.-76. (Cancelled)

77. (Previously presented) The method of claim 53 wherein the administering step further comprises administering dendritic cells.

78. (Previously presented) A method for inducing a immune response in a mammalian subject directed to a PSCA protein of Fig. 1B SEQ ID NO:2, the subject having a cancer overexpressing a Prostate Stem Cell Antigen (PSCA) protein, said cancer selected from the group consisting of prostate cancer, prostate cancer metastasized to bone, bladder cancer, and pancreatic cancer, the method comprising administering to the subject a PSCA protein of Fig. 1B (SEQ ID NO:2) or an immunogenic fragment thereof.

79. (Previously presented) The method of claim 78 wherein the immune response is a humoral response, whereby an antibody is produced.

80. (Previously presented) The method of claim 78, wherein the subject is a human.

81. (Previously presented) The method of claim 78, wherein the subject is a sheep, rat, dog, cat, pig, horse, or mouse.

82. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.

83. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

84. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.

85. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.

86. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.

87. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.

88. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.

89. (Canceled)

90. (Canceled)

91. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 99 as described in SEQ ID NO:2.

92. (Canceled)

93. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.

94. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.

95. (Previously presented) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.

96. (Currently amended) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 [[98]] as described in SEQ ID NO:2.

97. (Previously presented) The method of claim 78, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.

98. (New) The method of claim 53, wherein dendritic cells are used to present PSCA the protein or protein fragments to T cells in the context of MHC class I and II molecules.

99. (New) The method of claim 53, wherein the cancer is prostate cancer, prostate cancer metastasized to bone.

100. (New) The method of claim 78, wherein the immune response is a humoral immune response.